Tocilizumab (TCZ) is a humanized monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R) and was approved in 2009 by the European Medicines Agency (EMA) for the treatment of RA [40]. This evidence concerns the gene IL6R and rheumatoid arthritis.